Regulation & Compliance

A new high-tech facility in France aims to tackle the global mountain of textile waste, promising infinitely recyclable polyester and a greener future.

As Guardian Pharmacy Services prepares for a key investor conference, it showcases strong growth while its industry faces a looming crisis. Can its model work?

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?

A federal agency's safety warning has sparked a high-stakes legal fight, pitting a small business against regulators in a battle over science and survival.

Vitalist reports soaring losses and a $6.4M debt surge, raising 'going concern' alarms. Can its new Reebok smartwatches and VitalOS™ platform save it?

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

Lay's emotional 'Last Harvest' was America's top Super Bowl ad, but a new report reveals a huge generational divide, with Gen Z crowning a different winner.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

A jury verdict against Olin Corporation in a contract dispute with Shintech will cost the chemical giant $185 million and raises industry-wide questions.

The Midwest bank saw record earnings and shareholder returns in 2025, but a rise in nonperforming loans adds a layer of complexity to its growth story.

DifGen Pharmaceuticals' new FDA-approved generic eye drop is only the second of its kind, promising to increase competition and lower costs for patients.

With federal Grad PLUS loans ending July 2026, a Massachusetts agency is expanding its programs to prevent a major funding crisis for students.

As digitalization untethers companies, a fierce new competition among nations has begun. Who will win the battle for talent, capital, and the future?

In a landmark move, the FDA has removed major risk warnings from hormone therapy drugs, signaling a new era for women's health after decades of fear.

A nonprofit's Super Bowl ad with Mike Tyson declared war on processed food. Who's behind the campaign, and can it change how America eats?

Foreclosure filings jumped 32% from a year ago, with some states seeing alarming rates. Is this a market correction or a sign of a looming crisis?

Forget chatbots. Stardock's new app gives you persistent AI 'staff' on your PC that learn your workflow, promising a new era of private productivity.

For the eighth straight year, Tavant earns HousingWire's Tech100 award. We explore how its AI is setting a new standard for the entire housing industry.

As retirees seek safety from market swings, annuities are booming. But do these complex products deliver on their promises of secure, lifelong income?

With its first dedicated private credit fund, Brigade Capital is targeting a complex, underserved market segment to deliver what larger lenders often miss.